Multicentric reticulohistiocytosis (MRH) is a rare form of non-Langerhans histiocytosis that presents with erosive arthritis and skin nodules. Approximately 25% of patients with MRH have an associated malignancy. Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy. To date, 7 cases of MRH have been reported to present with cutaneous features of dermatomyositis. We describe an eighth patient with MRH who presented with dermatomyositis-like features (V-neck erythema, shawl sign, Gottron’s papules and periungual erythema), who developed metastatic breast cancer 1 year after diagnosis. We hypothesized that clinical overlap between MRH and dermatomyositis was not as uncommon as review of the literature suggested. Careful review of the physical exam findings and photographs of the 234 papers reporting MRH revealed 27 cases of MRH with dermatomyositis-like features. Of these 27 cases, 7 (26%) were associated with a malignancy. Skin biopsies of the cutaneous features mimicking dermatomyositis revealed pathologic features of MRH. This is a descriptive analysis of published case reports. Based on a review of published case reports, MRH presenting with dermatomyositis-like features is likely fairly common. Histological examination of skin biopsies allows for disease differentiation. Differentiating MRH from dermatomyositis is important for management decisions and comorbidity screening.

Keywords:
Dermatomyositis, Multicentric reticulohistiocytosis
1.
Tajirian AL, et al: Multicentric reticulohistiocytosis. Clin Dermatol 2006;24:486–492.
2.
Okiyama N, et al: Seborrheic area erythema as a common skin manifestation in Japanese patients with dermatomyositis. Dermatology 2008;217:374–377.
3.
Dugan EM, et al: Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009;15:1.
4.
McIlwain KL, et al: Multicentric reticulohistiocytosis with prominent cutaneous lesions and proximal muscle weakness masquerading as dermatomyositis. J Rheumatol 2005;32:193–194.
5.
Munoz-Santos C, et al: Multicentric reticulohistiocytosis-mimicking dermatomyositis. Case report and review of the literature. Dermatology 2007;214:268–271.
6.
Tait TJ, Bird HA, Ford GP: Multicentric reticulohistiocytosis: presentation with the cutaneous features of dermatomyositis. Br J Rheumatol 1994;33:100–101.
7.
Hsiung SH, et al: Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. J Am Acad Dermatol 2003;48(2 suppl):S11–S14.
8.
SantaLucia P, Helm MF: What is your diagnosis? Diagnosis: multicentric reticulohistiocytosis with dermatomyositislike features. Cutis 2009;84:246, 272–273.
9.
Benucci M, Sulla A, Manfredi M: Cardiac engagement in multicentric reticulohistiocytosis: report of a case with fatal outcome and literature review. Intern Emerg Med 2008;3:165–168.
10.
Barrow MV, Holubar K: Multicentric reticulohistiocytosis. A review of 33 patients. Medicine (Baltimore) 1969;48:287–305.
11.
Malik MK, et al: Proliferating multicentric reticulohistiocytosis associated with papillary serous carcinoma of the endometrium. J Am Acad Dermatol 2005;53:1075–1079.
12.
Kalajian AH, Callen JP: Multicentric reticulohistiocytosis successfully treated with infliximab: an illustrative case and evaluation of cytokine expression supporting anti-tumor necrosis factor therapy. Arch Dermatol 2008;144:1360–1366.
13.
Goto H, et al: Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect of bisphosphonate on histiocytes. Arthritis Rheum 2003;48:3538–3541.
14.
Badlissi F, Setty Y, Folzenlogen D: A case of multicentric reticulohistiocytosis initially misdiagnosed as lupus. J Clin Rheumatol 2002;8:232–233.
15.
Lonsdale-Eccles AA, et al: Successful treatment of multicentric reticulohistiocytosis with leflunomide. Br J Dermatol 2009;161:470–472.
16.
Yap FB: Multicentric reticulohistiocytosis in a Malaysian Chinese lady: a case report and review of literature. Dermatol Online J 2009;15:2.
17.
Ehrlich GE, et al: Multicentric reticulohistiocytosis (lipoid dermatoarthritis). A multisystem disorder. Am J Med 1972;52:830–840.
18.
Hiramanek N, Kossard S, Barnetson RS: Multicentric reticulohistiocytosis presenting with a rash and arthralgia. Australas J Dermatol 2002;43:136–139.
19.
Flam M, et al: Multicentric reticulohistiocytosis. Report of a case, with atypical features and electron microscopic study of skin lesions. Am J Med 1972;52:841–848.
20.
Mazzola G, et al: A case of multicentric reticulohistiocytosis. Clin Exp Rheumatol 1995;13:411–412.
21.
Conaghan P, et al: A unique presentation of multicentric reticulohistiocytosis in pregnancy. Arthritis Rheum 1993;36:269–272.
22.
Kenik JG, et al: Multicentric reticulohistiocytosis in a patient with malignant melanoma: a response to cyclophosphamide and a unique cutaneous feature. Arthritis Rheum 1990;33:1047–1051.
23.
Lesher JL Jr, Allen BS: Multicentric reticulohistiocytosis. J Am Acad Dermatol 1984;11:713–723.
24.
Liang GC, Granston AS: Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Arthritis Rheum 1996;39:171–174.
25.
Qureshi F, et al: Multicentric reticulohistiocytosis – A case report. Ir J Med Sci 1993;162:313–314.
26.
Catterall MD: Multicentric reticulohistiocytosis: a review of eight cases. Clin Exp Dermatol 1980;5:267–279.
27.
Cash JM, Tyree J, Recht M: Severe multicentric reticulohistiocytosis: disease stabilization achieved with methotrexate and hydroxychloroquine. J Rheumatol 1997;24:2250–2253.
28.
Trotta F, Castellino G, Lo Monaco A: Multicentric reticulohistiocytosis. Best Pract Res Clin Rheumatol 2004;18:759–772.
29.
Chen IJ, et al: Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009;28:639–646.
30.
Ideura G, et al: Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007;101:1406–1411.
31.
Klein RQ, et al: Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 2007;57:937–943.
32.
Mukae H, et al: Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009;136:1341–1347.
33.
Fathi M, et al: Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677–685.
34.
Werth VP, Bashir M, Zhang W: Photosensitivity in rheumatic diseases. J Investig Dermatol Symp Proc 2004;9:57–63.
35.
Matejicka C, Morgan GJ, Schlegelmilch JG: Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 2003;48:864–866.
36.
Kovach BT, et al: Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol 2004;140:919–921.
37.
Lee MW, et al: Successful treatment of multicentric reticulohistiocytosis with a combination of infliximab, prednisolone and methotrexate. Acta Derm Venereol 2004;84:478–479.
38.
Shannon SE, et al: Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol 2005;32:565–567.
39.
Klein R, et al: Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146:780–784.
40.
Flendrie M, et al: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666–R676.
41.
Hall HA, Zimmermann B: Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006;55:982–984.
42.
Ramos-Casals M, et al: Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847–861.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.